Preferred Label : catumaxomab;
MeSH note : Extracorporeal PBMNC coating with catumaxomab may be an option to control intravascular
cytokine release induced by therapeutic antibodies;
Is substance : O;
UNII : M2HPV837HO;
Origin ID : C522419;
UMLS CUI : C1831854;
ATC code(s)
CISMeF manual mappings
Exact mapping(s) to DCI
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
catumaxomab
catumaxomab
catumaxomab
drug approval
europe
product surveillance, postmarketing
antibodies, bispecific
antibodies, bispecific
Malignant Peritoneal Effusion
ascites
EPCAM protein, human
Epithelial Cell Adhesion Molecule
Intra-Abdominal infusions
T-cell Engaging Bispecific Antibody
adult
pregnancy
breast feeding
CD3 Complex
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=65788541
2012
France
summary of product characteristics
package leaflet
catumaxomab
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00125
2012
false
Canada
French
English
catumaxomab
catumaxomab
drug approval
canada
catumaxomab
infusions, parenteral
Intra-Abdominal infusions
antineoplastic agents
antineoplastic agents
antibodies, bispecific
antibodies, bispecific
Malignant ascites
ascites
ascites
summary of product characteristics
carcinoma
Epithelial Cell Adhesion Molecule
Epithelial Cell Adhesion Molecule
antigens, neoplasm
CD3 Complex
treatment outcome
randomized controlled trials as topic
risk assessment
drug evaluation
cell adhesion molecules
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=68214968
2012
France
summary of product characteristics
package leaflet
catumaxomab
---
https://www.ema.europa.eu/medicines/human/EPAR/Removab
2011
United Kingdom
French
English
syndication feed
EPCAM protein, human
drug compounding
catumaxomab
pregnancy
breast feeding
antibodies, monoclonal
antibodies, monoclonal
CD3 Complex
antigens, neoplasm
cell adhesion molecules
catumaxomab
drug approval
drug labeling
treatment outcome
antibodies, bispecific
antibodies, bispecific
pharmaceutical solutions
infusions, intravenous
ascites
neoplasms
catumaxomab
drug evaluation
summary of product characteristics
package leaflet
---
http://www.has-sante.fr/portail/jcms/c_941725/removab-catumaxomab-anticorps-monoclonal
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-01/removab_-_ct-6973.pdf
2009
France
French
catumaxomab
antibodies, bispecific
ascites
infusions, parenteral
antibodies, monoclonal
catumaxomab
carcinoma
antigens, neoplasm
CD3 Complex
neoplasms
treatment outcome
cell adhesion molecules
guidelines for drug use
evaluation of the transparency committee
---